Skip to main content
. Author manuscript; available in PMC: 2023 Aug 21.
Published in final edited form as: Urol Oncol. 2022 Apr 14;40(5):199.e15–199.e21. doi: 10.1016/j.urolonc.2022.03.013

Table 1.

Participants in bladder and kidney national cancer institute cooperative group trials and proportion of incidence cancer patients in the United States according to race/ethnicity, age, and sex, 2000 to 2019.

Characteristic Bladder and kidney cancer n = 14,094 Percent incident cancer in U.S. Bladder cancern = 5,468 Percent incident cancer in U.S. Kidney cancer n = 8,626 Percent incident cancer in U.S.
Race/ethnicity No (%) % No (%) % No (%) %
 Non-Hispanic White 12,169 (86.3%) 83.25% 4,780 (87.4%) 88.02% 7,389 (85.7%) 76.84%
 Black 662 (4.7%) 7.69% 232 (4.2%) 5.15% 420 (5.0%) 11.0%
 Hispanic 660 (4.7%) 6.06% 197 (3.6%) 4.03% 463 (5.4%) 8.79%
 Asian/Pacific Islander 312 (2.2%) 1.75% 143 (2.6%) 1.56% 169 (2.0%) 1.99%
 American Indian/Alaska Native 61 (0.4%) 0.51% 15 (0.3%) 0.29% 46 (0.5%) 0.81%
 Other 230 (1.6%) 0.74% 101 (1.8%) 0.94% 129 (1.5%) 0.48%
Age, years
 <65 7,902 (56.1%) 36.52% 2,196 (40.2%) 27.06% 5,706 (66.1%) 49.24%
 >65 6,192 (43.9%) 63.47% 3,272 (59.8%) 72.93% 2,920 (33.9%) 50.75%
Sex
 Female 3,701 (26.3%) 30.08% 1,134 (20.7%) 24.56% 2,567 (29.8%) 37.49%
 Male 10,393 (73.7%) 69.91% 4,334 (79.3%) 75.43% 6,059 (70.2%) 62.5%